SG11202000247SA - Neoantigen vaccine composition for treatment of cancer - Google Patents
Neoantigen vaccine composition for treatment of cancerInfo
- Publication number
- SG11202000247SA SG11202000247SA SG11202000247SA SG11202000247SA SG11202000247SA SG 11202000247S A SG11202000247S A SG 11202000247SA SG 11202000247S A SG11202000247S A SG 11202000247SA SG 11202000247S A SG11202000247S A SG 11202000247SA SG 11202000247S A SG11202000247S A SG 11202000247SA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- treatment
- vaccine composition
- neoantigen vaccine
- neoantigen
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17181026 | 2017-07-12 | ||
| EP17200036 | 2017-11-03 | ||
| PCT/EP2018/069047 WO2019012091A1 (en) | 2017-07-12 | 2018-07-12 | Neoantigen vaccine composition for treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202000247SA true SG11202000247SA (en) | 2020-02-27 |
Family
ID=62904488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202000247SA SG11202000247SA (en) | 2017-07-12 | 2018-07-12 | Neoantigen vaccine composition for treatment of cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200230220A1 (en) |
| EP (1) | EP3651798A1 (en) |
| JP (1) | JP7298926B2 (en) |
| KR (1) | KR20200027499A (en) |
| CN (1) | CN111093699A (en) |
| AU (1) | AU2018300051A1 (en) |
| BR (1) | BR112020000581A2 (en) |
| CA (1) | CA3069051A1 (en) |
| IL (1) | IL271965B2 (en) |
| MX (1) | MX2020000414A (en) |
| SG (1) | SG11202000247SA (en) |
| WO (1) | WO2019012091A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3703744A1 (en) * | 2017-11-03 | 2020-09-09 | Nouscom AG | Vaccine t cell enhancer |
| TW202043256A (en) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | Prostate neoantigens and their uses |
| CN113181351A (en) * | 2021-04-28 | 2021-07-30 | 广州赛佰澳生物医药科技有限公司 | Individual tumor therapeutic vaccine and preparation method thereof |
| WO2022242652A1 (en) * | 2021-05-18 | 2022-11-24 | Hung, Mien-Chie | Vaccine, use thereof and cancer vaccine cocktail |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030170850A1 (en) * | 2002-03-09 | 2003-09-11 | Cardone Michael H. | Cell-based screening methods |
| ATE449105T1 (en) | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | CHIMPANZEE ADENOVIRUS VACCINE CARRIAGE |
| PT1957528E (en) * | 2005-11-30 | 2013-01-09 | Univ Copenhagen | A nucleotide vaccine |
| BRPI0921927B8 (en) | 2008-11-21 | 2021-08-31 | Koebenhavns Univ University Of Copenhagen | Sensitization of an immune response |
| CN101481675B (en) * | 2009-01-06 | 2011-09-14 | 武汉大学 | Anti-swine fever multi-epitope DNA vaccine, construction method and use |
| ES2898235T3 (en) | 2009-02-02 | 2022-03-04 | Glaxosmithkline Biologicals Sa | Simian adenovirus nucleic acid and amino acid sequences, vectors containing them, and their uses |
| WO2012143499A2 (en) * | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Novel binder-drug conjugates (adcs) and their use |
| BR112013029834A8 (en) | 2011-05-24 | 2022-10-18 | Biontech Ag | individualized cancer vaccines |
| WO2014139587A1 (en) * | 2013-03-15 | 2014-09-18 | Okairòs Ag | Improved poxviral vaccines |
| CN103623396B (en) * | 2013-04-07 | 2016-03-02 | 安源生物科技(上海)有限公司 | Comprise the pharmaceutical composition of rt-PA |
| EP3328394A4 (en) * | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | Concatemeric peptide epitope rnas |
| CA3000313A1 (en) | 2015-10-08 | 2017-04-13 | The Governors Of The University Of Alberta | Hepatitis c virus e1/e2 heterodimers and methods of producing same |
| WO2017118702A1 (en) * | 2016-01-08 | 2017-07-13 | Vaccibody As | Neoepitope rna cancer vaccine |
-
2018
- 2018-07-12 MX MX2020000414A patent/MX2020000414A/en unknown
- 2018-07-12 IL IL271965A patent/IL271965B2/en unknown
- 2018-07-12 JP JP2020501243A patent/JP7298926B2/en active Active
- 2018-07-12 BR BR112020000581-9A patent/BR112020000581A2/en not_active Application Discontinuation
- 2018-07-12 SG SG11202000247SA patent/SG11202000247SA/en unknown
- 2018-07-12 CA CA3069051A patent/CA3069051A1/en active Pending
- 2018-07-12 AU AU2018300051A patent/AU2018300051A1/en active Pending
- 2018-07-12 EP EP18740213.6A patent/EP3651798A1/en active Pending
- 2018-07-12 WO PCT/EP2018/069047 patent/WO2019012091A1/en unknown
- 2018-07-12 KR KR1020207000604A patent/KR20200027499A/en not_active IP Right Cessation
- 2018-07-12 CN CN201880045959.3A patent/CN111093699A/en active Pending
- 2018-07-12 US US16/626,750 patent/US20200230220A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3651798A1 (en) | 2020-05-20 |
| IL271965A (en) | 2020-02-27 |
| NZ759944A (en) | 2023-08-25 |
| JP7298926B2 (en) | 2023-06-27 |
| RU2019144531A3 (en) | 2021-08-12 |
| JP2020532287A (en) | 2020-11-12 |
| RU2019144531A (en) | 2021-08-12 |
| MX2020000414A (en) | 2020-09-28 |
| AU2018300051A1 (en) | 2020-01-02 |
| IL271965B2 (en) | 2023-03-01 |
| CN111093699A (en) | 2020-05-01 |
| US20200230220A1 (en) | 2020-07-23 |
| CA3069051A1 (en) | 2019-01-17 |
| KR20200027499A (en) | 2020-03-12 |
| IL271965B (en) | 2022-11-01 |
| WO2019012091A1 (en) | 2019-01-17 |
| BR112020000581A2 (en) | 2020-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258955A (en) | Compositions and methods for treatment of cancer | |
| IL268814A (en) | Compositions and methods for treatment of cancer | |
| PL3622953T3 (en) | Combination treatment of cancer | |
| IL285077A (en) | Compounds for treatment of cancer | |
| HK1247931A1 (en) | Compositions and methods for diagnosis and treatment of cancer | |
| HK1251009B (en) | Therapeutic compositions of use for treating cancer | |
| IL271965A (en) | Neoantigen vaccine composition for treatment of cancer | |
| IL263793A (en) | Compounds and compositions for the treatment of cancer | |
| IL263835A (en) | Exosome-guided treatment of cancer | |
| IL261278A (en) | Pharmaceutical compositions for the treatment of cancer | |
| ZA201801022B (en) | Syd985 treatment of t-dm1 refractory cancer patients | |
| IL274748A (en) | Improved treatment of cancer | |
| IL255167A0 (en) | Compositions for the treatment of cancer | |
| HK1259029A1 (en) | Compositions having anti-fugetactic properties for treatment of cancer | |
| GB201819943D0 (en) | Immunotherapeutic treatment of cancer | |
| GB201704287D0 (en) | Treatment of cancer | |
| GB201703857D0 (en) | Treatment of cancer | |
| GB201702565D0 (en) | Treatment of cancer | |
| GB201704474D0 (en) | Combination therapy for treatment of cancer | |
| GB201622214D0 (en) | treatment of cancer | |
| GB201702139D0 (en) | Methods of cancer treatment | |
| GB201604621D0 (en) | Treatment of cancer | |
| GB201604293D0 (en) | Treatment of cancer | |
| IL236381A0 (en) | Pharmaceutical compositions for treatment of cancer | |
| GB201512723D0 (en) | Treatment of cancer |